Heres what to know: GLP-1 patches arent FDA-approved and dont contain real GLP-1-based medication
Body aches are not listed among the most common side effects of Zepbound (tirzepatide), but some patients report muscle aches or generalized body discomfort, particularly during the first few weeks of treatment or after dose increases
Economy M&A Politics SPACs IPOs Guidance Graphical News Global Macro Earnings Dividends - Funds Dividends - Stocks Debt/Share Issuance Commodities Buybacks Notable Calls Market Pulse Spotlight On The Move Trending News Top News News Navitas projects $13.5M Q3 revenue while targeting AI infrastructure at more than 1/3 of sales by year-end NVTS +4.49%Yesterday, 9:59 PM Sanmina targets $16B+ revenue in FY 2027 as it guides Q4 EPS of $3.05-$3.35 SANM +0.23%Yesterday, 9:39 PM Opko outlines $560M-$585M 2026 revenue guidance while planning MDX3001 clinical start by end of 2026 or early 2027 OPK +1.64%Yesterday, 9:29 PM Agilysys targets $368M-$373M FY 2027 revenue and at least 32% subscription growth following Q1 guidance raise AGYS +4.77%Yesterday, 8:19 PM Happen forecasts $1.80 to $1.90 EPS for 2026 amid raised originations target to $12.2B to $12.6B HAPN +3.82%Yesterday, 8:19 PM DoE issued emergency order for Southwest Power Pool grid to deploy backup power AEP -1.44%Yesterday, 8:18 PM4 Comments Kforce forecasts Q3 revenue of $349M-$357M and EPS of $0.71-$0.79 as technology demand improves KFRC +5.46%Yesterday, 8:10 PM Johnson & Johnson to pay up to $5.5B to settle talc lawsuits JNJ +0.97%Yesterday, 8:01 PM10 Comments Amkor projects Q3 2026 revenue of $1.95B-$2.05B with EPS of $0.72-$0.82 as Computing nears 30% sequential growth AMKR -6.54%Yesterday, 7:40 PM1 Comment Cadence signals 19% 2026 revenue growth amid record $8.1B backlog and expanding agentic AI partnerships CDNS +3.79%Yesterday, 7:39 PM Crude oil plunges after U.S
We address it before the damage accumulates
Malivindi, S
BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research Disclaimer IGF-1 LR3 is intended strictly for laboratory research and analytical purposes only
